Inventor · disambiguated record
Glenn Noronha
Also filed as: NORONHA GLENN
17 granted patents·21 pending applications·1,859 citations·filing 2001–2021
96Inventor score
Files withCLEARSIDE BIOMEDICAL INC14TARGEGEN INC13MEDTRONIC MINIMED INC3GONG XIANCHANG2NORONHA GLENN2
Top patents by PatentIndex Score
38 records- 0197US9931330B2Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2017·Granted Apr 3, 2018·37 cites·12 claims
- 0297US7528143B2Bi-aryl meta-pyrimidine inhibitors of kinasesTARGEGEN INC·Filed 2006·Granted May 5, 2009·220 cites·44 claims
- 0396US9636332B2Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2016·Granted May 2, 2017·26 cites·17 claims
- 0496US7045361B2Analyte sensing via acridine-based boronate biosensorsMEDTRONIC MINIMED INC·Filed 2001·Granted May 16, 2006·229 cites·21 claims
- 0596US6927246B2Polymers functionalized with fluorescent boronate motifs and methods for making themMEDTRONIC MINIMED INC·Filed 2002·Granted Aug 9, 2005·269 cites·26 claims
- 0695US9572800B2Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2016·Granted Feb 21, 2017·32 cites·13 claims
- 0795US8133900B2Use of bi-aryl meta-pyrimidine inhibitors of kinasesHOOD JOHN D·Filed 2008·Granted Mar 13, 2012·88 cites·26 claims
- 0895US7825246B2Bi-aryl meta-pyrimidine inhibitors of kinasesTARGEGEN INC·Filed 2007·Granted Nov 2, 2010·40 cites·9 claims
- 0995US6766183B2Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymersMEDTRONIC MINIMED INC·Filed 2001·Granted Jul 20, 2004·744 cites·46 claims
- 1094US8138199B2Use of bi-aryl meta-pyrimidine inhibitors of kinasesNORONHA GLENN·Filed 2008·Granted Mar 20, 2012·45 cites·31 claims
- 1192US8604042B2Bi-aryl meta-pyrimidine inhibitors of kinasesNORONHA GLENN·Filed 2010·Granted Dec 10, 2013·29 cites·5 claims
- 1291US7208493B2Vasculostatic agents and methods of use thereofTARGEGEN INC·Filed 2003·Granted Apr 24, 2007·68 cites·9 claims
- 1386US7691858B2Kinase inhibitors and methods of use thereofTARGEGEN INC·Filed 2007·Granted Apr 6, 2010·11 cites·7 claims
- 1485US8030487B22-amino—5-substituted pyrimidine inhibitorsTARGEGEN INC·Filed 2007·Granted Oct 4, 2011·10 cites·34 claims
- 1585US7456176B2Benzotriazine inhibitors of kinasesTARGEGEN INC·Filed 2005·Granted Nov 25, 2008·11 cites·34 claims
- 1678US12350261B2Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2021·Granted Jul 8, 2025·0 cites·23 claims
- 1773US2019240208A1Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 1873US2018325884A1Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 1972US2020383965A1Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2020·Application pending·0 cites
- 2070US2015258120A1Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2013·Application pending·0 cites
- 2167US2018092897A1Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2017·Application pending·0 cites
- 2261US2010278811A1Vasculostatic agents and methods of use thereofTARGEGEN INC·Filed 2009·Application pending·0 cites
- 2360US2018028516A1Methods and devices for the treatment of ocular diseases in human subjectsCLEARSIDE BIOMEDICAL INC·Filed 2017·Application pending·0 cites
- 2459US2022249517A1Compositions and methods for treating noninfectious uveitisCLEARSIDE BIOMEDICAL INC·Filed 2021·Application pending·0 cites
- 2558US2019269702A1Compositions and methods for treating noninfectious uveitisCLEARSIDE BIOMEDICAL INC·Filed 2019·Application pending·0 cites
- 2656US2007161645A1Thiazole inhibitors targeting resistant kinase mutationsTARGEGEN INC·Filed 2006·Application pending·0 cites
- 2755US2005282814A1Vasculostatic agents and methods of use thereofTARGEGEN INC·Filed 2005·Application pending·0 cites
- 2854US2007208019A1Vasculostatic agents and methods of use thereofTARGEGEN INC·Filed 2007·Application pending·0 cites
- 2954US2009275569A1Benzotriazine Inhibitors of KinasesGONG XIANCHANG·Filed 2008·Application pending·0 cites
- 3051US2007149508A1Six membered heteroaromatic inhibitors targeting resistant kinase mutationsTARGEGEN INC·Filed 2006·Application pending·0 cites
- 3151US2004074785A1Analyte sensors and methods for making themFiled 2002·Application pending·0 cites
- 3246US2010330030A1Vasculostatic Agents and Methods of Use ThereofTARGEGEN INC·Filed 2010·Application pending·0 cites
- 3343US8481536B2Benzotriazine inhibitors of kinasesGONG XIANCHANG·Filed 2010·Granted Jul 9, 2013·0 cites·5 claims
- 3443US2020316225A1Gene Therapy For Ocular ImprovementCOPERNICUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3541US2006247250A1Pyrimidine inhibitors of kinasesTARGEGEN INC·Filed 2006·Application pending·0 cites
- 3641US2023321024A1Methods of treating visual disorders using daily low dosing of a retinoid compoundELUMINEX BIOSCIENCES SUZHOU LTD·Filed 2021·Application pending·0 cites
- 3740US2019133933A1Formulations and methods for reduction of intraocular pressureCLEARSIDE BIOMEDICAL INC·Filed 2017·Application pending·0 cites
- 3835US2018042765A1Methods and devices for treating posterior ocular disordersCLEARSIDE BIOMEDICAL INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Glenn Noronha files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →